 |
|
|
|
 |
|
|
| Article 1 to 10 out of 10 concerning Takeda Pharmaceutical Company Limited
|
-
Kinaxo Biotechnologies Enters Agreement with Takeda
(04/23/2008)
Kinaxo Biotechnologies announced that it has entered an agreement with Takeda San Diego, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Osaka, Japan. Under the agreement, Kinaxo will make its KinaTor(TM) technology ...
-
Lu AA24530 for the treatment of mood and anxiety disorders enters into clinical phase II
(10/26/2007)
H. Lundbeck A/S and Takeda Pharmaceutical Company Limited announced the decision to investigate Lu AA24530 for the treatment of depression in patients. Based on positive, pre-clinical results, as well as the positive conclusion of the phase I trials ...
-
Swissmedic accepts Santhera's filing of SNT-MC17 in Friedreich's Ataxia
(10/05/2007)
Santhera Pharmaceuticals and Takeda Pharma AG announced that Swissmedic has accepted the filing of an application for authorization for Santhera's lead compound SNT-MC17 for the treatment of Friedreich's Ataxia (FRDA). SNT-MC17 has shown clinical ...
-
European EMEA acceptance of Marketing Authorization Application filing for SNT-MC17 in Friedreich's Ataxia by Santhera
(08/20/2007)
Santhera Pharmaceuticals and Takeda Pharmaceutical Company Limited (TSE:4502, "Takeda"), jointly announced that the European Medicines Agency (EMEA) has accepted the filing of the Marketing Authorization Application (MAA) for Santhera's lead ...
-
Santhera and Takeda Extend European Marketing Collaboration for SNT-MC17 into Duchenne Muscular Dystrophy
(08/06/2007)
Santhera Pharmaceuticals and Takeda Pharmaceutical Company Limited announced they have extended their existing commercialization partnership for SNT-MC17 (INN: idebenone) in the European Union and Switzerland to cover the compound's second ...
-
Evotec Reaches Second Milestone and Receives Success Payment in Alzheimer's Disease Collaboration with Takeda
(08/17/2006)
Evotec AG announced that the second milestone has been achieved in its four-year drug discovery collaboration with Takeda Pharmaceutical Company Limited. Evotec has granted Takeda exclusive rights to a novel target in Alzheimer's disease based on ...
-
Takeda and Galaxy Biotech Sign License Agreement for Galaxy's Investigational Antibodies for the Treatment of Cancer
(07/12/2006)
Takeda Pharmaceutical Company Limited and Galaxy Biotech, LLC announced that both parties have entered into an agreement for the development and marketing of HuL2G7, a humanized antiHepatocyte Growth Factor (HGF) monoclonal antibody created by ...
-
ARIUS Research Signs Anti-Cancer Antibody Discovery Deal with Takeda
(04/06/2006)
Three-Year Collaboration to look for Novel Cancer Treatments
ARIUS Research Inc. and Takeda Pharmaceutical Company Limited (Takeda) have entered into a three-year, multi-product collaboration using ARIUS' FunctionFIRST(TM) Platform to discover novel treatments for human disease.Under the terms of the ...
-
Santhera and Takeda Establish Collaboration to Develop and Market Idebenone (SNT-MC17) in Neuromuscular Disease
(08/04/2005)
Santhera Pharmaceuticals AG and Takeda Pharmaceutical Company Limited announced that they will collaborate to develop and commercialize Idebenone (SNT-MC17), a small molecule drug for the treatment of Friedreich's Ataxia ("FRDA"). The clinical ...
-
3M Pharmaceuticals and Takeda to Collaborate on Potential Treatment for Cervical High-Risk HPV Infection and Cervical Dysplasia
(03/03/2005)
3M and Takeda Pharmaceutical Company Limited announced that the two companies entered into an exclusive co-development and joint marketing agreement to collaborate on a potential topical treatment for cervical high-risk human papillomavirus (HPV) ...
|
|
|
|
|
Top